Protagonist (PTGX) is a high-conviction buy: late-stage icotrokinra & rusfertide near 2026 milestones, strong cash runway. Read more here.
In areas of high impact, 72% of patients with scalp psoriasis and 85% with genital psoriasis treated with icotrokinra achieved site-specific clear or almost clear skin at Week 52 in Phase 3 ...
Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose ...
Pharmaceutical Technology on MSN
Takeda and Protagonist seek FDA approval for rusfertide to treat PV
The NDA follows positive results from the Phase III global placebo-controlled, randomised VERIFY trial.
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist’s proprietary discovery platform have completed Phase 3 ...
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist’s proprietary discovery platform are currently in advanced ...
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist’s proprietary discovery platform are currently in advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results